Christopher R. M. Asquith - Search Results

Year	Number of Results
2014	2
2015	1
2016	1
2017	1
2018	3
2019	14
2020	9
2021	10
2022	1

1

eEF2K: an atypical kinase target for cancer.

Temme L, Asquith CRM. Temme L, et al. Among authors: asquith crm. Nat Rev Drug Discov. 2021 Aug;20(8):577. doi: 10.1038/d41573-021-00124-5. Nat Rev Drug Discov. 2021. PMID: 34257429 No abstract available.

2

Optimization of 4-Anilinoquinolines as Dengue Virus Inhibitors.

Huang PT, Saul S, Einav S, Asquith CRM. Huang PT, et al. Among authors: asquith crm. Molecules. 2021 Dec 3;26(23):7338. doi: 10.3390/molecules26237338. Molecules. 2021. PMID: 34885921 Free PMC article.

3

BCKDK: an emerging kinase target for metabolic diseases and cancer.

East MP, Laitinen T, Asquith CRM. East MP, et al. Among authors: asquith crm. Nat Rev Drug Discov. 2021 Jul;20(7):498. doi: 10.1038/d41573-021-00107-6. Nat Rev Drug Discov. 2021. PMID: 34117456 No abstract available.

4

CDC42BPA/MRCKα: a kinase target for brain, ovarian and skin cancers.

East MP, Asquith CRM. East MP, et al. Among authors: asquith crm. Nat Rev Drug Discov. 2021 Mar;20(3):167. doi: 10.1038/d41573-021-00023-9. Nat Rev Drug Discov. 2021. PMID: 33558670 No abstract available.

5

RIOK2: straddling the kinase/ATPase line.

Asquith CRM, East MP, Zuercher WJ. Asquith CRM, et al. Nat Rev Drug Discov. 2019 Jul;18(8):574. doi: 10.1038/d41573-019-00107-7. Nat Rev Drug Discov. 2019. PMID: 31367048 No abstract available.

6

Potent antiviral activity of novel multi-substituted 4-anilinoquin(az)olines.

Saul S, Pu SY, Zuercher WJ, Einav S, Asquith CRM. Saul S, et al. Among authors: asquith crm. Bioorg Med Chem Lett. 2020 Aug 15;30(16):127284. doi: 10.1016/j.bmcl.2020.127284. Epub 2020 May 27. Bioorg Med Chem Lett. 2020. PMID: 32631507

7

PKMYT1: a forgotten member of the WEE1 family.

Asquith CRM, Laitinen T, East MP. Asquith CRM, et al. Nat Rev Drug Discov. 2020 Mar;19(3):157. doi: 10.1038/d41573-019-00202-9. Nat Rev Drug Discov. 2020. PMID: 32127662 No abstract available.

8

STK19: a new target for NRAS-driven cancer.

Asquith CRM, Temme L. Asquith CRM, et al. Nat Rev Drug Discov. 2020 Sep;19(9):579. doi: 10.1038/d41573-020-00116-x. Nat Rev Drug Discov. 2020. PMID: 32587355 No abstract available.

9

Design and evaluation of 1,2,3-dithiazoles and fused 1,2,4-dithiazines as anti-cancer agents.

Maffuid KA, Koyioni M, Torrice CD, Murphy WA, Mewada HK, Koutentis PA, Crona DJ, Asquith CRM. Maffuid KA, et al. Among authors: asquith crm. Bioorg Med Chem Lett. 2021 Jul 1;43:128078. doi: 10.1016/j.bmcl.2021.128078. Epub 2021 May 2. Bioorg Med Chem Lett. 2021. PMID: 33951490

10

PIKfyve: a lipid kinase target for COVID-19, cancer and neurodegenerative disorders.

Huang PT, Einav S, Asquith CRM. Huang PT, et al. Among authors: asquith crm. Nat Rev Drug Discov. 2021 Oct;20(10):730. doi: 10.1038/d41573-021-00158-9. Nat Rev Drug Discov. 2021. PMID: 34504321 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results